Xin Gao, MD, Assistant Professor, Harvard Medical School, Genitourinary Cancers Program, Mass General Cancer Center, commented on the results from TROPHY-U-01 cohort 2.

“These data add to the overall data on the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer. This cohort included patients whose disease progressed after checkpoint inhibitor therapy and were platinum-ineligible at the start of the study. Half of the patients did receive prior neoadjuvant or adjuvant platinum therapy, and 18% received prior enfortumab vedotin. In this patient population, sacituzumab govitecan yielded an objective response rate of 32% [primary endpoint], which is consistent with the previously reported data from TROPHY-U-01 cohort 1 [patients with metastatic urothelial cancer whose disease progressed after prior platinum- and checkpoint inhibitor–based therapies] that led to accelerated approval by the FDA in 2021,” he said.

Xin Gao, MD

Dr. Gao continued: “The clinical benefit rate, median progression-free survival rate, and medial overall survival rate compare favorably with available data for other active therapies such as enfortumab vedotin in the checkpoint inhibitor–treated population. The safety profile in this study was consistent with the known profile for sacituzumab govitecan from the prior TROPHY-U-01 cohort 1 data.”

“This abstract further supports the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer following checkpoint inhibitor therapy. I eagerly await the results of the TROPiCS-04 randomized phase III trial of sacituzumab govitecan vs physician’s choice single-agent chemotherapy in patients with metastatic urothelial cancer after prior platinum and checkpoint inhibitor therapies,” Dr. Gao concluded. 

DISCLOSURE: Dr. Gao has served as a consultant or advisor to Bayer, Guardant Health, Flare Therapeutics, Silverback Therapeutics, PathAI, PureTech, and Myovant Sciences; and has served as principal investigator at his institution, which has received research funding from Arvinas, Exelixis, Pfizer, Harpoon Therapeutics, Aprea Therapeutics, Takeda, Aravive, Merck, Poseida Therapeutics, TopAlliance BioSciences, Novartis, Regeneron, and Bayer.